Background: Sclerostin (SC) is a monomeric glycoprotein expressed by osteocytes that affects bone formation. Recent studies have suggested a potential role for this protein in the pathophysiology of vascular diseases. The aim of the present study was to investigate SC expression in atherosclerotic plaques of patients affected by severe atherosclerotic disease who underwent carotid endarterectomy. We also evaluated possible differences in SC expression between patients with and without type 2 diabetes (T2D). Methods: This was a cross-sectional study involving 46 patients aged 55 to 80 years (mean, 71.1 ± 6.7 years, 36 men, 15 patients with T2D) who underwent carotid endarterectomy. Immunohistochemical levels of SC were evaluated in the atherosclerotic plaques by double-staining immunochemistry, and serum SC levels were evaluated by enzyme-linked immunosorbent assay. Results: Sclerostin was present in the atherosclerotic plaques of all subjects investigated and increased significantly in the media compared with the intima (P < 0.0001) as well as in vascular smooth muscle cells (VSMCs) compared with the infiltrating macrophages (P < 0.0001). However, no significant difference in SC expression was observed between patients with and without T2D. No correlation was found between serum and immunohistochemical levels of SC; significantly increased SC serum levels were detected in males compared with females (P = 0.049). Conclusions: We have demonstrated, for the first time, the expression of SC in VSMCs of atherosclerotic plaques, suggesting a potential role for this protein in the development of atherosclerosis. Further studies are needed to understand if the role played by SC is detrimental or protective in the atherosclerotic disease process.

Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy / Leto, Gaetano; D'Onofrio, Luca; Lucantoni, Federica; Zampetti, Simona; Campagna, Giuseppe; Foffi, Chiara; Moretti, Chiara; Carlone, Angela; Palermo, Andrea; Leopizzi, Martina; Porta, Natale; Massucci, Marco; Lenzi, Andrea; Bertoletti, Giovanni Battista; Rocca, Carlo Della; Buzzetti, Raffaella. - In: DIABETES/METABOLISM RESEARCH AND REVIEWS. - ISSN 1520-7552. - 35:1(2019), pp. 1-7. [10.1002/dmrr.3069]

Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy

Leto, Gaetano;D'Onofrio, Luca;Lucantoni, Federica;Zampetti, Simona;Campagna, Giuseppe;Foffi, Chiara;Moretti, Chiara;Carlone, Angela;Palermo, Andrea;Leopizzi, Martina;Porta, Natale;Massucci, Marco;Lenzi, Andrea;Rocca, Carlo Della;Buzzetti, Raffaella
2019

Abstract

Background: Sclerostin (SC) is a monomeric glycoprotein expressed by osteocytes that affects bone formation. Recent studies have suggested a potential role for this protein in the pathophysiology of vascular diseases. The aim of the present study was to investigate SC expression in atherosclerotic plaques of patients affected by severe atherosclerotic disease who underwent carotid endarterectomy. We also evaluated possible differences in SC expression between patients with and without type 2 diabetes (T2D). Methods: This was a cross-sectional study involving 46 patients aged 55 to 80 years (mean, 71.1 ± 6.7 years, 36 men, 15 patients with T2D) who underwent carotid endarterectomy. Immunohistochemical levels of SC were evaluated in the atherosclerotic plaques by double-staining immunochemistry, and serum SC levels were evaluated by enzyme-linked immunosorbent assay. Results: Sclerostin was present in the atherosclerotic plaques of all subjects investigated and increased significantly in the media compared with the intima (P < 0.0001) as well as in vascular smooth muscle cells (VSMCs) compared with the infiltrating macrophages (P < 0.0001). However, no significant difference in SC expression was observed between patients with and without T2D. No correlation was found between serum and immunohistochemical levels of SC; significantly increased SC serum levels were detected in males compared with females (P = 0.049). Conclusions: We have demonstrated, for the first time, the expression of SC in VSMCs of atherosclerotic plaques, suggesting a potential role for this protein in the development of atherosclerosis. Further studies are needed to understand if the role played by SC is detrimental or protective in the atherosclerotic disease process.
atherosclerotic plaques; sclerostin; type 2 diabetes; Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
01 Pubblicazione su rivista::01a Articolo in rivista
Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy / Leto, Gaetano; D'Onofrio, Luca; Lucantoni, Federica; Zampetti, Simona; Campagna, Giuseppe; Foffi, Chiara; Moretti, Chiara; Carlone, Angela; Palermo, Andrea; Leopizzi, Martina; Porta, Natale; Massucci, Marco; Lenzi, Andrea; Bertoletti, Giovanni Battista; Rocca, Carlo Della; Buzzetti, Raffaella. - In: DIABETES/METABOLISM RESEARCH AND REVIEWS. - ISSN 1520-7552. - 35:1(2019), pp. 1-7. [10.1002/dmrr.3069]
File allegati a questo prodotto
File Dimensione Formato  
Leto_Sclerostin_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 368.41 kB
Formato Adobe PDF
368.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1206405
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 20
social impact